Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Center For Neuromusculoskeletal Restorative Medicine Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners within 1 distinct art unit. This concentration in a single art unit suggests a very specific technical focus for the company's current prosecution.
The busiest examiner is MOSHER, ERIC PARKER, who is responsible for 1 pending office action. With 2 distinct examiners each handling the same number of active matters, the workload is evenly split. This means that each examiner's approach will affect exactly half of the company's active pending portfolio.
The fact that both of the 2 distinct examiners are located in 1 distinct art unit is a key detail for practitioners. It implies that while there are different individuals to negotiate with, the overarching policies and supervisory environment of the art unit will be consistent across the pending office actions. This Biotechnology & Pharmaceuticals portfolio is currently navigating a very focused examination path, with 1 examiner assigned to each matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844067 | COMPOUNDS FOR THE MEASUREMENT OF THE OXYGEN CONCENTRATION | MOSHER, ERIC PARKER | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844067 | COMPOUNDS FOR THE MEASUREMENT OF THE OXYGEN CONCENTRATION | MOSHER, ERIC PARKER | — | §101§103§112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18592683 | USE OF MARAVIROC IN PREPARATION OF DRUGS FOR TREATMENT OF MUSCLE DEGENERATIVE DISEASES | SHIAO, REI TSANG | 1691 | §103 | Final Rejection | — | Pending | Mar 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial